GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Equity-to-Asset

BioVaxys Technology (XCNQ:BIOV) Equity-to-Asset : -0.44 (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioVaxys Technology's Total Stockholders Equity for the quarter that ended in Jul. 2023 was C$-0.62 Mil. BioVaxys Technology's Total Assets for the quarter that ended in Jul. 2023 was C$1.41 Mil.

The historical rank and industry rank for BioVaxys Technology's Equity-to-Asset or its related term are showing as below:

XCNQ:BIOV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.89   Med: 0.74   Max: 0.97
Current: -0.44

During the past 5 years, the highest Equity to Asset Ratio of BioVaxys Technology was 0.97. The lowest was -0.89. And the median was 0.74.

XCNQ:BIOV's Equity-to-Asset is ranked worse than
88.94% of 1555 companies
in the Biotechnology industry
Industry Median: 0.67 vs XCNQ:BIOV: -0.44

BioVaxys Technology Equity-to-Asset Historical Data

The historical data trend for BioVaxys Technology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Equity-to-Asset Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
Equity-to-Asset
-0.70 0.62 0.91 0.96 -0.89

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 -0.89 -0.49 0.34 -0.44

Competitive Comparison of BioVaxys Technology's Equity-to-Asset

For the Biotechnology subindustry, BioVaxys Technology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Equity-to-Asset falls into.



BioVaxys Technology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

BioVaxys Technology's Equity to Asset Ratio for the fiscal year that ended in Oct. 2022 is calculated as

Equity to Asset (A: Oct. 2022 )=Total Stockholders Equity/Total Assets
=-0.774/0.866
=

BioVaxys Technology's Equity to Asset Ratio for the quarter that ended in Jul. 2023 is calculated as

Equity to Asset (Q: Jul. 2023 )=Total Stockholders Equity/Total Assets
=-0.624/1.413
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVaxys Technology  (XCNQ:BIOV) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


BioVaxys Technology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (XCNQ:BIOV) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.
Executives
James Passin Director, Senior Officer

BioVaxys Technology (XCNQ:BIOV) Headlines

No Headlines